Deerfield Management Company, L.P. (Series C) Recursion Pharmaceuticals, Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $4.04 Billion
- Q4 2024
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 2,315,000 shares of RXRX stock, worth $15.5 Million. This represents 0.39% of its overall portfolio holdings.
Number of Shares
2,315,000
Previous 2,315,000
-0.0%
Holding current value
$15.5 Million
Previous $15.3 Million
2.58%
% of portfolio
0.39%
Previous 0.28%
Shares
1 transactions
Others Institutions Holding RXRX
# of Institutions
342Shares Held
284MCall Options Held
2.83MPut Options Held
3.64M-
Vanguard Group Inc Valley Forge, PA34MShares$227 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl32.3MShares$216 Million1.91% of portfolio
-
Baillie Gifford & CO24.9MShares$166 Million0.13% of portfolio
-
Black Rock Inc. New York, NY17.3MShares$116 Million0.0% of portfolio
-
Softbank Group Corp Minato Ku Tokyo, M014.7MShares$98 Million0.44% of portfolio
About RECURSION PHARMACEUTICALS, INC.
- Ticker RXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 180,480,000
- Market Cap $1.21B
- Description
- Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...